Literature DB >> 17376308

Study of the SH3-domain GRB2-like 2 gene expression in laryngeal carcinoma.

Chao Shang1, Wei-neng Fu, Yan Guo, Dai-fa Huang, Kai-lai Sun.   

Abstract

BACKGROUND: Laryngeal carcinoma is a common malignant tumor of the upper respiratory tract, and in 95% of cases the tumor is laryngeal squamous cell carcinoma (LSCC). The abnormity of SH3-domain GRB2-like 2 (SH3GL2) gene was found in LSCC. In order to clarify the relationship between SH3GL2 gene and LSCC, we evaluated the expression of the SH3GL2 gene in LSCC.
METHOD: Real-time PCR, immunohistochemistry and Western blotting were used to detect the mRNA and protein expression and find the various rules of SH3GL2 gene in LSCC.
RESULTS: The result of real-time PCR showed that the expression level of SH3GL2 mRNA in LSCC tissue was apparently down-regulated; immunohistochemical analysis showed that SH3GL2 protein was mainly located in cytoplasm, the rate of positive cells and SH3GL2 protein expression level were fluctuated with the pathological classification of LSCC; the result of Western blotting showed that SH3GL2 protein was down-regulated significantly in LSCC samples, especially in metastatic lymph nodes.
CONCLUSIONS: These results suggest that SH3GL2 is a LSCC related gene and its expression level is fluctuated with the pathological classification which indicate that SH3GL2 participates in the development and progression of LSCC. And it may be considered as a novel tumor marker to find both a new anti-oncogene and relative factors of invasion and metastasis of laryngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376308

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  6 in total

1.  Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma.

Authors:  Nicola Potter; Aikaterini Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic N P Thompson; Thomas S Jacques; Brian Harding; David G T Thomas; Rodger W Palmer; Jeremy Rees; John Darling; Tracy J Warr
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

2.  Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.

Authors:  Adrien Daigeler; Daigeler Adrien; Ludger Klein-Hitpass; Klein-Hitpass Ludger; Ingo Stricker; Stricker Ingo; Oliver Müller; Müller Oliver; Cornelius Kuhnen; Kuhnen Cornelius; Ansgar Michael Chromik; Chromik Ansgar Michael; Lars Steinstraesser; Steinstraesser Lars; Ole Goertz; Goertz Ole; Hans-Ulrich Steinau; Steinau Hans-Ulrich; Marcus Lehnhardt; Lehnhardt Marcus
Journal:  Langenbecks Arch Surg       Date:  2009-01-22       Impact factor: 3.445

3.  Aberrant promoter methylation of SH3GL2 gene in vulvar squamous cell carcinoma correlates with clinicopathological characteristics and HPV infection status.

Authors:  Bo Li; Yinghui He; Xue Han; Shitai Zhang; Yan Xu; Yang Zhou; Zixuan Song; Ling Ouyang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion.

Authors:  Xing-Hua Che; Hong Chen; Zhen-Ming Xu; Chao Shang; Kai-Lai Sun; Wei-Neng Fu
Journal:  BMC Cancer       Date:  2010-06-19       Impact factor: 4.430

5.  Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling.

Authors:  Yufu Zhu; Xiang Zhang; Lei Wang; Zhe Ji; Manyi Xie; Xinyu Zhou; Zhiyi Liu; Hengliang Shi; Rutong Yu
Journal:  J Cell Mol Med       Date:  2017-05-04       Impact factor: 5.310

6.  Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.

Authors:  Guru Prasad Maiti; Pinaki Mondal; Nupur Mukherjee; Amlan Ghosh; Susmita Ghosh; Sanjib Dey; Jayanta Chakrabarty; Anup Roy; Jaydip Biswas; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.